Loading
journalsJournal
Cancer Research
Cancer Research is AACR's original journal, publishing since 1941: broad basic and preclinical cancer biology, tumour immunology and the AACR annual meeting abstracts.
Also called: Cancer Ressrc-cancer-research
Overview
Cancer Research (Cancer Res) is the original journal of the American Association for Cancer Research (AACR), publishing since 1941, appearing twice a month and available on a hybrid model with articles free a year after publication. It covers broad basic and preclinical cancer biology, including the tumour microenvironment, tumour immunology, preclinical therapeutics and computational cancer biology, and it publishes the AACR annual meeting abstract supplement. Its readers are laboratory cancer biologists and preclinical researchers. Within OnCo it has its own Cancer Research source feed, is tied to the AACR institution entry and is linked from the Shari Pilon-Thomas and Evanthia Galanis biographies, and a reader would use it for preclinical biology and the AACR meeting abstracts.
Publisher
American Association for Cancer Research · American Association for Cancer Research
Scope
basic cancer biology
Website
Access model
hybrid
Founded
1941
ISSN
0008-5472
Impact factor (2023)
12.5 · Clarivate Journal Citation Reports 2024 (2023 JIF)
review2020981 citations
The Frequency of Ras Mutations in Cancer
One bottleneck page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
methods20174,751 citations
Li 2017: TIMER, a web server for estimating immune cells in tumour genomic data
TIMER made immune infiltration analysis accessible to any group with tumour expression data, which is why it is cited so heavily; it is a standard first step in linking a gene or mutation to the immune state of a cancer.
basic201574 citations
A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
One term page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observational20145,519 citations
Rahib 2014: projecting US cancer incidence and deaths to 2030
This paper reframed pancreatic and liver cancer as the coming burden and is cited in most arguments for investing in them. Its pancreatic cancer projection has been tracking close to reality in the years since.
basic2009700 citations
Adaptive therapy
One technology page and one term page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observational20081,105 citations
A history of cancer chemotherapy
One roadmap page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
translational1987284 citations
Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer
The reason a normal CA 19-9 never rules pancreatic cancer out, why Lewis-negative patients need a different marker (CA 125, CEA or CA 19-9-independent panels), and a constraint on every blood-based detection idea on this page.
translational1941changed practice
Huggins and Hodges 1941: the effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
The origin of hormone therapy for cancer, and the reason prostate cancer is treated by taking something away rather than adding a cytotoxic drug. More than eighty years later, every man who starts androgen deprivation is having this experiment repeated on him, and the disease is still defined by whether it has stopped responding to it.
Alberto Gabizon
Oncologist, Shaare Zedek Medical Center; professor, Hebrew University-Hadassah Medical School
Liposomal drug deliveryPharmacokinetics of nanomedicinesOvarian and breast cancer
The clinician half of the partnership that turned a liposome chemistry idea into Doxil, and the person who did the trials that showed it behaved differently in patients from free doxorubicin.
Dorraya El-Ashry
Chief Scientific Officer
Breast cancer biologyTumour microenvironmentResearch strategy
Breast cancer biologist and Chief Scientific Officer of the Breast Cancer Research Foundation, directing its global research grant portfolio.
Evanthia Galanis
Group Chair, Alliance for Clinical Trials in Oncology; Professor of Oncology, Mayo Clinic
Neuro-oncologyOncolytic virusesCooperative group trials
Evanthia Galanis is a brain tumour specialist who chairs one of the largest US clinical trial networks.
Haiko Bloemendal
Representative of Radboudumc Centre for Oncology to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Haiko Bloemendal represents Radboudumc Centre for Oncology in the Organisation of European Cancer Institutes, which lists the centre among its members in The Netherlands.
Koichi Fukunaga
Director General
Respiratory medicineHospital leadershipLung disease
Respiratory physician who heads Keio University Hospital in Tokyo, a leading Japanese academic hospital with designated cancer centre status.
Krisztina Bogos
Representative of National Korányi Institute for Pulmonology to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Krisztina Bogos represents National Korányi Institute for Pulmonology in the Organisation of European Cancer Institutes, which lists the organisation among its members in Hungary.
Louis Chesler
Executive Director, Children's Cancer Institute
Paediatric oncologyNeuroblastomaPaediatric drug development
Paediatric oncologist and neuroblastoma researcher who leads Children's Cancer Institute in Sydney, Australia's dedicated childhood cancer research institute.
Shari Pilon-Thomas
Senior Member, Immunology; Scientific Director, Cellular Therapy
TIL therapyTumour immunologyImmunotherapy resistance
Shari Pilon-Thomas is the immunologist behind Moffitt's TIL manufacturing and the biology of who responds.
Notes
top- Holds: Oldest AACR journal: preclinical and mechanistic cancer science. Access: Paywalled.
reviewCancer Research 2020981 citations
The Frequency of Ras Mutations in Cancer
One bottleneck page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
basicCancer Research 201574 citations
A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
One term page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
basicCancer Research 2009700 citations
Adaptive therapy
One technology page and one term page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observationalCancer Research 20081,105 citations
A history of cancer chemotherapy
One roadmap page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
translationalCancer Research 1987284 citations
Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer
The reason a normal CA 19-9 never rules pancreatic cancer out, why Lewis-negative patients need a different marker (CA 125, CEA or CA 19-9-independent panels), and a constraint on every blood-based detection idea on this page.
translationalCancer Research 1941changed practice
Huggins and Hodges 1941: the effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
The origin of hormone therapy for cancer, and the reason prostate cancer is treated by taking something away rather than adding a cytotoxic drug. More than eighty years later, every man who starts androgen deprivation is having this experiment repeated on him, and the disease is still defined by whether it has stopped responding to it.
Similar pages
institutions
collections
people
key papers
A history of cancer chemotherapyA Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical EfficacyAdaptive therapyHuggins and Hodges 1941: the effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostateRelationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancerThe Frequency of Ras Mutations in Cancer